BIZARRE: Is gilead sciences stock underperforming the dow - You Need To See This

Valued at a market cap of $98.6 billion, Gilead Sciences, Inc. (GILD) discovers, develops, and commercializes medicines in the areas of unmet medical need. The California-based company is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases, and inflammation/respiratory diseases.

Companies valued at $10 billion or more are generally labeled as “large-cap” stocks, and Gilead Sciences fits this criterion perfectly. Gilead Sciences is working on diversifying and growing its business beyond antivirals into other therapeutic areas through strategic collaborations and acquisitions and research and development programs.